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investigating the leukemic role of NOTCH1, a topic of pressing
clinical and scientific interest.
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Nuclear entrapment of BCR–ABL by combining imatinib mesylate with leptomycin B
does not eliminate CD34þ chronic myeloid leukaemia cells
Leukemia (2009) 23, 1006–1008; doi:10.1038/leu.2008.367;
published online 8 January 2009
Chronic myeloid leukaemia (CML) arises from the formation of
the Philadelphia (Phþ ) chromosome in haematopoietic
stem cells. The translated fusion oncoprotein, BCR–ABL
(p210BCRABL), is a constitutively active tyrosine kinase (TK),
which activates multiple proliferative and anti-apoptotic signalling
pathways, causing deregulated cell growth.1 Despite impressive
rates of complete cytogenetic response (CCyR) in the majority of
patients treated with the targeted TK inhibitor (TKI), imatinib
mesylate (IM; Glivec, Novartis, Basle, Switzerland),2 few
patients achieve sustained molecular remission and a significant
proportion develops resistance to IM.3 The presence of pre-
existing or acquired BCR–ABL kinase domain mutations, which
decrease IM binding,3 and the innate insensitivity of primitive
quiescent CML stem cells to IM4 are two contributing resistance
mechanisms. Consequently, many strategies have been investi-
gated to overcome IM resistance, including the development
of second-generation TKIs, nilotinib (Tasigna, Novartis) and
dasatinib (Sprycel, Bristol–Myers Squibb, Princeton, NJ, USA),
although these remain ineffective against the T315I mutation.
In search of alternative strategies for the elimination of Phþ
cells, Vigneri and Wang 5showed an intriguing strategy of
tricking BCR-ABLþ cells into committing cell death. This
mechanism was based on the observation that on treatment
with IM, inactive BCR-ABL translocates into the cell nucleus.
Entrapment of BCR–ABL there, coupled with re-activation of its
TK activity, reversed its role to that of an activator of apoptosis.
On the basis of the mounting evidence that BCR–ABLþ stem
cells are not eliminated by novel targeted therapies, such as IM
and the second-generation TKIs, we investigated whether
combination treatment of IM, with the nuclear export inhibitor
leptomycin B (LMB Calbiochem), could drive CML CD34þ cells
into apoptosis.
Our initial experiments, over a period of 16 days, on the
effects of IM, LMB and the combination of these drugs on the
Phþ cell line K562, showed that treatment with either drug
alone for the first 72 h was at least cytostatic. However, 5–8 days
after drug washout, cells were able to recover, an effect not
seen with the drug combination,in which irreversible growth
Table 1 Summary of t(9;14) cases
Case Diagnosis Age (years) Cell line Reference
1 T-cell neoplasiaa 20 HD-MAR 4
2 T-ALL 32 HT-1 5
3 T-ALL 24 F 8
4 T-ALL 23 F 9
5 T-ALL 29 F 9
6 T-CLL Unknown F 10
Abbreviations: ALL, acute lymphocytic leukemia; CLL, chronic
lymphocytic leukemia; HD, heterodimerization domain.
aAfter Hodgkin’s lymphoma.
Letters to the Editor
1006
Leukemia
inhibition was observed (day 16, untreated: 9.4±3.7 109;
10mM IM: 1.6±0.4 105; 10 nM LMB: 2.3±2.2 107; 10mM
IMþ 10 nM LMB: 0.4±0.3 103 cells; (Figure 1a). This is
consistent with the findings of Wang and Vigneri,5 although
we observed complete loss of viable cells at a later time point
(day 14) than that reported earlier (day 9). K562 cells, exposed
to the combination of IM and LMB, showed evidence of
BCR–ABL localization within the nucleus. Western blot analysis
confirmed that levels of nuclear BCR–ABL were significantly
higher in cells treated with IM and LMB, compared with the
untreated control (Po0.05) (Figure 1bi). Significant reduction of
cytoplasmic BCR–ABL after exposure to IM and LMB was not
detectected by western blot (Figure 1bii).
Earlier, the efficacy of the two-drug treatment was compared
in myeloid progenitors from the bone marrow of CML patients
versus normal CD34þ samples.6 These data showed that this
combination preferentially targeted BCR–ABL-expressing cells,
by producing the greatest decrease in the number of Phþ
compared with Ph colonies. In this study, we report the effect
of IM and LMB directly on CML CD34þ cells by evaluating the
toxicity of this drug regime on these cells rather than the
cytostatic effect studied in colony-forming assays by Aloisi
et al.6 Exposure of total CD34þ cells (obtained from leukapheresis
material (495% CD34þ ) from chronic phase (CP) CML patients
with written informed consent) to the combination of IM with
LMB failed to eliminate these cells (Figure 1c), despite the fact
that nuclear localization of BCR–ABL was detected (Figure 1d).
However, a 1-log reduction in total cell number, compared with
input, resulted 3 days after drug washout (Figure 1c). In
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Figure 1 Effect of imatinib mesylate and Leptomycin B treatment on cell growth and localization of BCR–ABL in CML cell lines and primary cells.
(a) The Phþ cell line K562 recovers from exposure to IM and LMB as single agents but not when used in combination. K562 cells seeded at
2 105/ml in 3-ml cultures were treated with IM (10 mM), LMB (10 nM), or both drugs simultaneously, in duplicate wells for 72 h before drug
washout with phosphate buffer saline (PBS). Cells were re-seeded in the absence of further drug addition and counted, by trypan blue
dye exclusion, at 2–3-day intervals, for a total of 16 days. Results were analysed by paired Student’s t-test and are presented as the mean of
three experiments±s.e.m. (b) BCR–ABL protein is present in the nuclear fraction of K562 cells after IM and LMB exposure. 5 106 K562 cells were
pre-treated with 5 mM IM, 5 nM LMB, or both, for 4 h and sub-fractionated using the ProteoExtract Subcellular Proteome Extraction Kit (Calbiochem,
Merck Biosciences Ltd, Hull, UK) into (i) nuclear and (ii) cytoplasmic fractions. Extracts were analysed by western blotting. Nuclear and
cytoplasmic BCR–ABL (anti-ABL 8E9 antibody (BD Ltd, Oxford, UK)) protein levels were expressed as the ratio of ABL to the loading controls,
histone1 (anti-Histone H1, clone AE-4 (Upstate Millipore Ltd, UK)) and pan-actin antibody (Cell-Signalling, Hertfordshire, UK), for nuclear and
cytoplasmic fractions, respectively, as determined by densitometry. Each blot is representative of three independent experiments. Results were
analysed by paired Student’s t-test and are presented as the mean of three experiments±s.e.m. The asterisk (n) indicates significantly different
protein ratios from the untreated control (Po 0.05) ,I,: IM; L: LMB. (c) Growth of CML CD34þ cells is not irreversibly inhibited by simultaneous
exposure to IM and LMB. Identical time-course experiments to those in (a) were set up for three CML patient-derived CD34þ cells over a total of 16
days. Cells seeded at 5 105/ml in 2-ml cultures were treated with no drug, 10mM IM, 10 nM LMB, or both, for 72 h before drug washout with PBS
and counted at 2–3-day intervals thereafter. Results were analysed by paired Student’s t-test and are presented as the mean of three
experiments±s.e.m. (d) BCR–ABL protein is present in the nucleus of CML CD34þ cells after IM and LMB exposure. CML CD34þ cells before (i)
and after exposure to 24 h IM (10 mM) with LMB (10 nM) added for the last 12 h (ii). This shows the nuclear import of BCR–ABL (anti-ABL 8E9, BD,
as above) (red) after combined treatment with IM and LMB in comparison with the cytoplasmic localization in the untreated cells. The green
signals correspond to Phalloidin-conjugated Alexa Fluor 488 staining of F-actin (Molecular Probes, Invitrogen, Paisley, UK) with blue (DAPI)
staining for DNA. (e) LMB induces cytostasis in non-CML CD34þ cells. Duplicate wells seeded at 5 105 cells/ml of CD34þ cells from normal
autologous donors were cultured with no drug, 10mM IM, 10 nM LMB, or both drugs, for 72 h, as for CML CD34þ cells, before drug washout.
Results were analysed by paired Student’s t-test and are presented as the mean of three experiments±s.e.m.
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produced a similar inhibitory effect to that of the drug
combination on CML CD34þ cell viability.6 However, LMB
also inhibited the proliferation of BCR–ABL CD34þ cells by
three-to fivefold, showing a cytostatic effect with recovery 3
days after drug washout, demonstrating the non-specific toxicity
of this drug (Figure 1e). This result suggests that CML CD34þ
cells seem to be more sensitive to inhibition of nuclear export
than BCR–ABL CD34þ cells. The recovery of both CML and
non-CML cells after drug washout could be explained by the de
novo synthesis of CRM1, which reversed the LMB effect.7 As
anticipated, Phþ CD34þ cells were less sensitive than K562
cells to IM exposure, showing the persistence/resistance of these
stem and progenitor cells in the presence of IM. IM led to a
non-significant reduction in the viable Ph CD34þ population
(20%) (P40.05) after both 3-day exposure and 13 days
after drug washout (40%) (P40.05), corroborating an earlier
report in which exposure (3 days) to 10 mM IM did not
significantly reduce the expansion of Ph CD34þ cells.8
Furthermore, as the combination treatment failed to eliminate
the total CML CD34þ cells, its effect on the more primitive
quiescent leukaemic stem cells (CD34þ38 or equivalent) was
not investigated.
In conclusion, our results indicate that even the manipulation
of the cellular localization of BCR–ABL is not sufficient to
induce cell death of all the Phþ CD34þ cell population. It is
possible that the combination of IM and LMB would be more
effective if a selective inhibitor of the ABL nuclear export signal
were available.
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No evidence of frequent association of the JAK2 V617F mutation with acute myocardial
infarction in young patients
Leukemia (2009) 23, 1008–1009; doi:10.1038/leu.2008.368;
published online 8 January 2009
Myeloproliferative neoplasms (MPNs) have been associated
with high incidence of thrombosis and bleeding episodes, which
significantly contribute to disease-related morbidity and mortality.1
Notably, clinical data indicate an association of the JAK2 V617F
mutation, seen in nearly all polycythemia vera cases and half of
those with essential thrombocythemia with erythrocytosis,
leukocytosis and thrombotic complications. Particularly for
essential thrombocythemia, a recent overview has suggested
that the JAK2 V617F positivity may be associated with an
increased risk of thrombosis, an effect mediated by the
leukocytosis conferred by the mutation.2 Several studies have
indicated that a substantial proportion of patients with
idiopathic Budd–Chiari syndrome, portal vein or mesenteric
vein thrombosis carry the JAK2 V617F mutation, even in the
absence of overt clinical or hematological features of an MPN.3
Detection of JAK2 V617F mutation in this setting is a marker of a
‘latent’ MPN as positive patients appear to have bone marrow
histological features characteristic of MPN.3,4
Recently, Mercier et al. screened 27 patients aged o40 years,
who had experienced an acute myocardial infarction (AMI).
Three out of 27 (11.1%) patients carried the JAK2 V617F
mutation, leading the authors to conclude that a latent MPN
may often be present in this group of patients, warranting
screening for the V617F mutation.5 In contrast, in a study of 28
patients with AMI at a young age (defined as o50 years), none
was found to harbour the JAK2 V617F mutation. That group of
patients was part of a larger cohort of patients with arterial or
venous thrombosis outside the splanchnic circulation. The study
suggested that screening for JAK2 V617F mutation is not
warranted as part of the hypercoagulable work-up in patients
with non-splanchnic thrombosis.6
We investigated the prevalence of the JAK2 V617F mutation in a
prospectively assembled cohort of AMI patients aged o35 years.
We hypothesized that JAK2 V617F may be further enriched in this
group of patients as it represents a good model because the mainly
genetic factors, and to a lesser extent the environmental factors,
have an impact on the pathogenesis of the thrombosis. We studied
consecutive patients admitted to our institution between January
1998 and December 2005 who had suffered their first AMI under
the age of 35 years. DNA was extracted from peripheral blood
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